| CAS: | 86541-74-4 | |||||
| 分子式: | C24H28N2O5 · HCl | |||||
| 分子量: | 460.95 | |||||
| 英文名称: |
|
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| B887820 | MACKLIN | 盐酸贝那普利 | ≥ 98 % HPLC | 75元/1g; 285元/5g; 1335元/25g; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
储存:室温 状态:白色到灰白色粉末 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| B3611 | TCI | Benazepril Hydrochloride | >98.0%(T)(HPLC) | 290元/1G; 990元/5G; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
技术规格
物性(参考值)
相关法规
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 127998 | J&K | Benazepril Hydrochloride | 98.5%, 一种长效的血管紧张素转换酶 (ACE) 抑制剂 | 941元/1G; 3278元/5G; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
产品描述 Benazepril HCl是一种用于治疗高血压的药物。 靶点(IC50 & Targe) ACE 体外研究 在自发性高血压大鼠(SHR)中,Benazepril hydrochloride(3或10 mg/kg/天,口服14天)剂量依赖性地抑制去甲肾上腺素(NE)连续输注所引起的血压增加,并且抑制单胺氧化酶抑制剂tranylcypromine诱导的癫痫。[1] 在正常血压大鼠中,Benazepril hydrochloride(30 毫克/千克,口服)减小甘油三酯和总胆固醇水平。在胆固醇喂养的兔子中,Benazepril hydrochloride(3 毫克/千克,皮下注射)导致主动脉粥样硬化显著减少,而不会降低高胆固醇血症。在正常血压大鼠中,Benazepril hydrochloride(100 毫克/千克,口服)对尿量和尿中电解质排泄量没有影响,但会降低PSP排泄。在DOCA/盐自发性高血压大鼠中,Benazepril hydrochloride(10 毫克/千克,口服)抑制尿蛋白排泄的增加。[3] 在实验诱导或自发产生的慢性肾功能衰竭的猫中,Benazepril hydrochloride给药校正系统性高血压并显著降低血管紧张素II和醛甾酮。在实验诱导或自发产生的慢性肾功能衰竭的猫中,Benazepril hydrochloride降低了血清肌酸酐和尿蛋白浓度。[4] 在性肾功能衰竭犬残肾模型中,Benazepril hydrochloride显著降低血压,血管紧张素II和醛甾酮并增大施用中断到服药前水平。[5] 参考文献 [1] Yamamoto S, et al. Arzneimittelforschung,?991, 41(6), 602-607. [2] Yamamoto S, et al. Arzneimittelforschung,?991, 41(9), 913-923. [3] Watanabe T, et al. J Vet Med Sci,?007, 69(10), 1015-1023. [4] Mishina M, et al. J Vet Med Sci,?008, 70(5), 455-460. 安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Y0001025 | Benazepril Hydrochloride | European Pharmacopoeia (EP) Reference Standard | 1572.27元/ ; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. 生化/生理作用 贝那普利是一种长效的血管紧张素转换酶 (ACE) 抑制剂。 包装 Unit quantity: 170 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 注意 Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Y0001038 | Benazepril for system suitability | European Pharmacopoeia (EP) Reference Standard | 1572.27元/ ; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. 生化/生理作用 贝那普利是一种长效的血管紧张素转换酶 (ACE) 抑制剂。 包装 Unit quantity: 0.016 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 注意 Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| B0935 | Sigma-Aldrich | Benazepril Hydrochloride | ≥98% (HPLC), solid | 7725.74元/250 MG; 13531.6元/500 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 包装 250, 500 mg in glass bottle 生化/生理作用 贝那普利是一种长效的血管紧张素转换酶 (ACE) 抑制剂。 特点和优势 This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PHR1912 | Supelco | Benazepril Hydrochloride | Pharmaceutical Secondary Standard; Certified Reference Material | 2252.27元/250 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards 生化/生理作用 贝那普利是一种长效的血管紧张素转换酶 (ACE) 抑制剂。 分析说明 These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. 其他说明 This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. 附注 To see an example of a Certificate of Analysis for this material enter LRAB0978 in the Documents slot below. This is an example certificate only and may not be the lot that you receive. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1048619 | USP | Benazepril Hydrochloride | United States Pharmacopeia (USP) Reference Standard | 3231.47元/125 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. 生化/生理作用 贝那普利是一种长效的血管紧张素转换酶 (ACE) 抑制剂。 分析说明 These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||